000 | 01968 a2200505 4500 | ||
---|---|---|---|
005 | 20250516130917.0 | ||
264 | 0 | _c20131104 | |
008 | 201311s 0 0 eng d | ||
022 | _a1521-009X | ||
024 | 7 |
_a10.1124/dmd.112.048488 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aZamek-Gliszczynski, Maciej J | |
245 | 0 | 0 |
_aPharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. _h[electronic resource] |
260 |
_bDrug metabolism and disposition: the biological fate of chemicals _cApr 2013 |
||
300 |
_a714-26 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Multicenter Study | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Agents _xmetabolism |
650 | 0 | 4 |
_aBile _xmetabolism |
650 | 0 | 4 | _aDogs |
650 | 0 | 4 |
_aFeces _xchemistry |
650 | 0 | 4 |
_aGlycogen Synthase Kinase 3 _xantagonists & inhibitors |
650 | 0 | 4 | _aGlycogen Synthase Kinase 3 beta |
650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xpharmacokinetics |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMaleimides _xpharmacokinetics |
650 | 0 | 4 |
_aMicrosomes, Liver _xmetabolism |
650 | 0 | 4 |
_aProtein Kinase Inhibitors _xmetabolism |
650 | 0 | 4 | _aRats |
650 | 0 | 4 |
_aUrine _xchemistry |
700 | 1 | _aAbraham, Trent L | |
700 | 1 | _aAlberts, Jeffrey J | |
700 | 1 | _aKulanthaivel, Palaniappan | |
700 | 1 | _aJackson, Kimberley A | |
700 | 1 | _aChow, Kay H | |
700 | 1 | _aMcCann, Denis J | |
700 | 1 | _aHu, Haitao | |
700 | 1 | _aAnderson, Shelby | |
700 | 1 | _aFurr, Nathan A | |
700 | 1 | _aBarbuch, Robert J | |
700 | 1 | _aCassidy, Kenneth C | |
773 | 0 |
_tDrug metabolism and disposition: the biological fate of chemicals _gvol. 41 _gno. 4 _gp. 714-26 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1124/dmd.112.048488 _zAvailable from publisher's website |
999 |
_c22408643 _d22408643 |